---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-165297"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2026-04-21T23:59:59+00:00"
generated_at: "2026-05-15T05:08:11.782712+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Erasca narrows ERAS-0015 Phase 1 data readout timeline to mid-May 2026

## Summary
- Narrowed Phase 1 monotherapy data readout for pan-RAS molecular glue ERAS-0015 to no later than mid-May 2026 (prior: first half 2026).
- Data from two trials: Erasca's AURORAS-1 (RAS-mutant solid tumors) and Joyo's JYP0015M101 (China, specific RAS mutations).
- No financial or regulatory update; no safety or efficacy data disclosed yet.

## SEC filing metadata
- accession: 0001193125-26-165297
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2026-04-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000119312526165297/0001193125-26-165297-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000119312526165297/eras-20260421.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-165297
- JSON: https://secwatch.observer/filing/0001193125-26-165297.json
- Plain text: https://secwatch.observer/filing/0001193125-26-165297.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.